We work closely with healthcare professionals to develop robotic solutions for treating vascular diseases such as heart attack and stroke. Our first solution, R-One™, is designed to assist with PCI, the gold standard for coronary artery diseases.
Doctor J. Fajadet, co-director of the cardiovascular disease department at the Clinique Pasteur in Toulouse (France), co-director of EuroPCR congress and Director of the EAPCI
R-One™ is a very intuitive tool. Getting started is very fast and simple. In particular, R-One™ allows instruments to be locked into place, so you never lose access to the lesion. It brings a significant revolution in our profession.
Doctor R. Sabatier, interventional cardiologist at Caen University Hospital (France)
Getting started is very easy and intuitive. The fact that the robot’s behavior is consistent and means the risk of human error can be reduced.
Professor A. Cribier, Former Chief of the cardiology department at the university hospital of Rouen, conceived and developed the TAVI
R-One™ represents a major step forward in interventional cardiology. This technology really impressed me and will give strong benefits to the healthcare system.
Doctor A. Cremonesi, head of the Villa Maria hospital cardiovascular department in Bologna (Italy) and active member of EuroPCR Board
This robotic platform is very impressive. It’s the future of our profession, not only for interventional cardiology, but also for peripheral vascular and neurovascular procedures.
Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. As an active player in the evolving medical robotics industry, these innovative solutions aim to make medical procedures safer thanks to reliable technologies, while complementing manual interventions. R-One™ is the first solution developed by Robocath. It uses a unique technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed. R-One is designed to operate with precision and perform specific movements, creating better interventional conditions. Thanks to its open architecture, R-One is compatible with market-leading devices and cath labs. In a prospective, randomized, controlled pre-clinical trial, R-One demonstrated safety and efficacy as it achieved 100% technical procedure success and no MACE (major adverse cardiovascular events). R-One received the CE marking in February 2019 and started its clinical application in September 2019. Currently R-One is available in Europe and Africa. Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all. Based in Rouen, France, Robocath has more than 70 employees.